HemaCare Corp. announced that its registration statementcovering resale of 155,000 shares of common stock relating to arecent private placement was declared effective by theSecurities and Exchange Commission.

This represents the domestic part of a $2 million Regulation Dand Regulation S offering, completed May 7, in which theremainder of 400,000 shares were sold offshore.

The Los Angeles company (NASDAQ:HEMA) provideshemapheresis-derived blood products and services and hasbeen testing a passive hyperimmune therapy product fortreating AIDS, Immupath, since 1990. HemaCare is awaitingapproval by the California State Department of Health Service'sFood and Drug Branch for Phase III extension of the study.

(c) 1997 American Health Consultants. All rights reserved.